March 17, 2020 10:21 AM EDTUpdated 10:48 AM

Merck touts PhIII data burnishing $500M platform — what kind of bar does it set for a chronic cough drug?

Amber Tong

Roy Baynes surprised some analysts during Merck’s investor day last June — its first in five years — when he shone a surprising spotlight on gefapixant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck touts PhIII data burnishing $500M platform — what kind of bar does it set for a chronic cough drug?

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

Mer­ck touts PhI­II da­ta bur­nish­ing $500M plat­form — what kind of bar does it set for a chron­ic cough drug?

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Merck touts PhIII data burnishing $500M platform — what kind of bar does it set for a chronic cough drug?

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?